KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Acadia Pharmaceuticals' Liabilities and Shareholders Equity rose 3622.83% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year increase of 3952.53%. This contributed to the annual value of $1.2 billion for FY2024, which is 5858.82% up from last year.
  • Acadia Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.3 billion in Q3 2025, which was up 3622.83% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Liabilities and Shareholders Equity peaked at $1.3 billion during Q3 2025, and registered a low of $587.8 million during Q4 2022.
  • In the last 5 years, Acadia Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $724.4 million in 2021 and averaged $822.5 million.
  • In the last 5 years, Acadia Pharmaceuticals' Liabilities and Shareholders Equity crashed by 1733.67% in 2022 and then skyrocketed by 5858.82% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $700.1 million in 2021, then fell by 16.04% to $587.8 million in 2022, then grew by 27.41% to $749.0 million in 2023, then soared by 58.59% to $1.2 billion in 2024, then increased by 12.04% to $1.3 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.1 billion for Q1 2025.